GERON CORP Deferred Tax Liabilities, Net
GERON CORP (GERN) had Deferred Tax Liabilities, Net of $682.00 thousand as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilities · last filed 2025-02-27
- 2024-12-31: Deferred Tax Liabilities, Net $682.00K.
- 2023-12-31: Deferred Tax Liabilities, Net $1.00M.
- 2022-12-31: Deferred Tax Liabilities, Net $1.10M.
- 2021-12-31: Deferred Tax Liabilities, Net $1.30M.
| Period end | Deferred Tax Liabilities, Net |
|---|---|
| 2024-12-31 | $682.00K 10-K · filed 2025-02-27 |
| 2023-12-31 | $1.00M 10-K · filed 2025-02-27 |
| 2022-12-31 | $1.10M 10-K · filed 2024-02-28 |
| 2021-12-31 | $1.30M 10-K · filed 2023-03-16 |
| 2020-12-31 | $1.40M 10-K · filed 2022-03-10 |
| 2019-12-31 | $600.00K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |